Efficacy of Long-Term β-Blocker Therapy for Secondary Prevention of Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery

Heng Zhang, Xin Yuan, Haibo Zhang, Sipeng Chen, Yan Zhao, Kun Hua, Chenfei Rao, Wei Wang, Hansong Sun, Shengshou Hu, Zhe Zheng, Heng Zhang, Xin Yuan, Haibo Zhang, Sipeng Chen, Yan Zhao, Kun Hua, Chenfei Rao, Wei Wang, Hansong Sun, Shengshou Hu, Zhe Zheng

Abstract

Background: Conflicting results from recent observational studies have raised questions concerning the benefit of β-blockers for patients undergoing coronary artery bypass grafting (CABG). Furthermore, the efficacy of long-term β-blocker therapy in CABG patients after hospital discharge is uncertain.

Methods and results: The study included 5926 consecutive patients who underwent CABG and were discharged alive. The prevalence and consistency of β-blocker use were determined in patients with and without a history of myocardial infarction (MI). β-Blockers were always used in 1280 patients (50.9%) with and 1642 patients (48.1%) without previous MI after CABG. Compared with always users (n=2922, 49.3%), the risk of all-cause death was significantly higher among inconsistent β-blocker users (hazard ratio [HR], 1.96; 95% confidence interval [CI], 1.50-2.57), and never using β-blockers was associated with increased risk of both all-cause death (HR, 1.42; 95% CI, 1.01-2.00) and the composite of adverse cardiovascular events (HR, 1.29; 95% CI, 1.10-1.50). In the cohort without MI, the HR for all-cause death was 1.70 (95% CI, 1.17-2.48) in inconsistent users and 1.23 (95% CI, 0.76-1.99) in never users. In the MI cohort, mortality was higher for inconsistent users (HR, 2.14; 95% CI, 1.43-3.20) and for never users (HR, 1.59; 95% CI, 1.07-2.63). Consistent results were obtained in equivalent sensitivity analyses.

Conclusions: In patients with or without previous MI undergoing CABG, the consistent use of β-blockers was associated with a lower risk of long-term mortality and adverse cardiovascular events. Strategies should be developed to understand and improve discharge prescription of β-blockers and long-term patient adherence.

Keywords: adrenergic beta-antagonists; coronary artery bypass; coronary artery disease; myocardial infarction.

© 2015 The Authors.

Figures

Figure 1.
Figure 1.
Kaplan–Meier curves of outcomes associated with β-blocker use after coronary artery bypass graft surgery. Shown are rates of all-cause death and major adverse cardiac and cerebrovascular events (MACCEs) in the overall population (A), patients without pervious myocardial infarction (MI; B), and patients with pervious MI (C). The P values were calculated with the log-rank test on the basis of all available follow-up data with always users as reference.
Figure 2.
Figure 2.
Hazard ratios (HRs) associated with β-blockers in prespecified subgroups of patients. Subgroup analyses were performed with the use of Cox proportional hazards regression with the always user group as reference and with adjustment for all patient-level variables in Table I in the online-only Data Supplement. The HRs were reported for inconsistent users or never users with always users as reference. CI indicates confidence interval; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; and MACCE, major adverse cardiac and cerebrovascular events.

References

    1. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–1390.
    1. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Are beta-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction? Arch Intern Med. 2000;160:947–952.
    1. Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, Cigarroa JE, Disesa VJ, Hiratzka LF, Hutter AM, Jr, Jessen ME, Keeley EC, Lahey SJ, Lange RA, London MJ, Mack MJ, Patel MR, Puskas JD, Sabik JF, Selnes O, Shahian DM, Trost JC, Winniford MD American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; Society of Cardiovascular Anesthesiologists; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58:e123–e210. doi: 10.1016/j.jacc.2011.08.009.
    1. Guru V, Anderson GM, Fremes SE, O’Connor GT, Grover FL, Tu JV Canadian CABG Surgery Quality Indicator Consensus Panel. The identification and development of Canadian coronary artery bypass graft surgery quality indicators. J Thorac Cardiovasc Surg. 2005;130:1257–1264.
    1. Shahian DM, Edwards FH, Ferraris VA, Haan CK, Rich JB, Normand SL, DeLong ER, O’Brien SM, Shewan CM, Dokholyan RS, Peterson ED Society of Thoracic Surgeons Quality Measurement Task Force. Quality measurement in adult cardiac surgery, part 1: conceptual framework and measure selection. Ann Thorac Surg. 2007;83(suppl):S3–S12. doi: 10.1016/j.athoracsur.2007.01.053.
    1. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL REACH Registry Investigators. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308:1340–1349. doi: 10.1001/jama.2012.12559.
    1. Andersson C, Mérie C, Jørgensen M, Gislason GH, Torp-Pedersen C, Overgaard C, Køber L, Jensen PF, Hlatky MA. Association of β-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwide cohort study. JAMA Intern Med. 2014;174:336–344. doi: 10.1001/jamainternmed.2013.11349.
    1. Andersson C, Shilane D, Go AS, Chang TI, Kazi D, Solomon MD, Boothroyd DB, Hlatky MA. β-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol. 2014;64:247–252. doi: 10.1016/j.jacc.2014.04.042.
    1. Brinkman W, Herbert MA, O’Brien S, Filardo G, Prince S, Dewey T, Magee M, Ryan W, Mack M. Preoperative β-blocker use in coronary artery bypass grafting surgery: national database analysis. JAMA Intern Med. 2014;174:1320–1327. doi: 10.1001/jamainternmed.2014.2356.
    1. Brinkman WT, Herbert MA, Prince SL, Magee MJ, Dewey TM, Smith RL, Edgerton JR, Head SJ, Ryan WH, Mack MJ. Preoperative beta-blocker usage: is it really worthy of being a quality indicator? Ann Thorac Surg. 2011;92:788–795. doi: 10.1016/j.athoracsur.2011.03.088.
    1. LaPar DJ, Crosby IK, Kron IL, Kern JA, Fonner E, Jr, Rich JB, Speir AM, Ailawadi G. Preoperative beta-blocker use should not be a quality metric for coronary artery bypass grafting. Ann Thorac Surg. 2013;96:1539–1544.
    1. Smith SC, Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol. 2011;58:2432–2446.
    1. Kulik A, Ruel M, Jneid H, Ferguson TB, Hiratzka LF, Ikonomidis JS, Lopez-Jimenez F, McNallan SM, Patel M, Roger VL, Sellke FW, Sica DA, Zimmerman L American Heart Association Council on Cardiovascular Surgery and Anesthesia. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation. 2015;131:927–964. doi: 10.1161/CIR.0000000000000182.
    1. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter AM, Jr, Lytle BW, Marlow RA, Nugent WC, Orszulak TA, Antman EM, Smith SC, Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Ornato JP American College of Cardiology/American Heart Association Task Force on Practice Guidelines Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery; American Society for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol. 2004;44:e213–e310. doi: 10.1016/j.jacc.2004.07.021.
    1. Li Y, Zheng Z, Hu S Chinese Coronary Artery Bypass Grafting Registry Study. The Chinese Coronary Artery Bypass Grafting Registry Study: analysis of the national multicentre database of 9248 patients. Heart. 2009;95:1140–1144. doi: 10.1136/hrt.2008.146563.
    1. Zhang H, Yuan X, Osnabrugge RL, Meng D, Gao H, Zhang S, Rao C, Hu S, Zheng Z. Influence of diabetes mellitus on long-term clinical and economic outcomes after coronary artery bypass grafting. Ann Thorac Surg. 2014;97:2073–2079. doi: 10.1016/j.athoracsur.2014.02.047.
    1. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166:1842–1847. doi: 10.1001/archinte.166.17.1842.
    1. Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross JT, Jr, Drozda JP, Jr, Fesmire FM, Fintel DJ, Fonarow GC, Fox KA, Gray DT, Harrington RA, Hicks KA, Hollander JE, Krumholz H, Labarthe DR, Long JB, Mascette AM, Meyer C, Peterson ED, Radford MJ, Roe MT, Richmann JB, Selker HP, Shahian DM, Shaw RE, Sprenger S, Swor R, Underberg JA, Van de Werf F, Weiner BH, Weintraub WS American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards; American College of Emergency Physicians; Emergency Nurses Association; National Association of Emergency Medical Technicians; National Association of EMS Physicians; Preventive Cardiovascular Nurses Association; Society for Cardiovascular Angiography and Interventions; Society of Cardiovascular Patient Care; Society of Thoracic Surgeons. 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). Circulation. 2013;127:1052–1089. doi: 10.1161/CIR.0b013e3182831a11.
    1. Li F, Zaslavsky AM, Landrum MB. Propensity score weighting with multilevel data. Stat Med. 2013;32:3373–3387. doi: 10.1002/sim.5786.
    1. Ferguson TB, Jr, Coombs LP, Peterson ED Society of Thoracic Surgeons National Adult Cardiac Surgery Database. Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America. JAMA. 2002;287:2221–2227.
    1. Foody JM, Ferdinand FD, Galusha D, Rathore SS, Masoudi FA, Havranek EP, Nilasena D, Radford MJ, Krumholz HM. Patterns of secondary prevention in older patients undergoing coronary artery bypass grafting during hospitalization for acute myocardial infarction. Circulation. 2003;108(suppl 1):II24–II28. doi: 10.1161/01.cir.0000087654.26917.00.
    1. Goyal A, Alexander JH, Hafley GE, Graham SH, Mehta RH, Mack MJ, Wolf RK, Cohn LH, Kouchoukos NT, Harrington RA, Gennevois D, Gibson CM, Califf RM, Ferguson TB, Jr, Peterson ED PREVENT IV Investigators. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. Ann Thorac Surg. 2007;83:993–1001. doi: 10.1016/j.athoracsur.2006.10.046.
    1. Connolly SJ, Cybulsky I, Lamy A, Roberts RS, O’brien B, Carroll S, Crystal E, Thorpe KE, Gent M Beta-Blocker Length Of Stay (BLOS) Study. Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: the Beta-Blocker Length Of Stay (BLOS) study. Am Heart J. 2003;145:226–232. doi: 10.1067/mhj.2003.147.
    1. Halonen J, Hakala T, Auvinen T, Karjalainen J, Turpeinen A, Uusaro A, Halonen P, Hartikainen J, Hippeläinen M. Intravenous administration of metoprolol is more effective than oral administration in the prevention of atrial fibrillation after cardiac surgery. Circulation. 2006;114(suppl):I1–I4. doi: 10.1161/CIRCULATIONAHA.105.000851.
    1. MACB Study Group. Effect of metoprolol on death and cardiac events during a 2-year period after coronary artery bypass grafting. Eur Heart J. 1995;16:1825–1832.
    1. Sjöland H, Caidahl K, Lurje L, Hjalmarson A, Herlitz J. Metoprolol treatment for two years after coronary bypass grafting: effects on exercise capacity and signs of myocardial ischaemia. Br Heart J. 1995;74:235–241.
    1. Angeloni E, Melina G, Roscitano A, Refice S, Capuano F, Lechiancole A, Comito C, Benedetto U, Sinatra R. β-Blockers improve survival of patients with chronic obstructive pulmonary disease after coronary artery bypass grafting. Ann Thorac Surg. 2013;95:525–531. doi: 10.1016/j.athoracsur.2012.07.080.
    1. Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113:203–212. doi: 10.1161/CIRCULATIONAHA.105.505636.
    1. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177–186. doi: 10.1001/jama.297.2.177.
    1. Setoguchi S, Glynn RJ, Avorn J, Mittleman MA, Levin R, Winkelmayer WC. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol. 2008;51:1247–1254. doi: 10.1016/j.jacc.2007.10.063.
    1. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2014. 2014;35:2541–2619.
    1. Chan AY, McAlister FA, Norris CM, Johnstone D, Bakal JA, Ross DB Alberta Provincial Program for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. Effect of beta-blocker use on outcomes after discharge in patients who underwent cardiac surgery. J Thorac Cardiovasc Surg. 2010;140:182–187.
    1. Hlatky MA, Solomon MD, Shilane D, Leong TK, Brindis R, Go AS. Use of medications for secondary prevention after coronary bypass surgery compared with percutaneous coronary intervention. J Am Coll Cardiol. 2013;61:295–301. doi: 10.1016/j.jacc.2012.10.018.
    1. Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008;117:1028–1036. doi: 10.1161/CIRCULATIONAHA.107.706820.
    1. Hiratzka LF, Eagle KA, Liang L, Fonarow GC, LaBresh KA, Peterson ED Get With the Guidelines Steering Committee. Atherosclerosis secondary prevention performance measures after coronary bypass graft surgery compared with percutaneous catheter intervention and nonintervention patients in the Get With the Guidelines database. Circulation. 2007;116(suppl):I207–I212. doi: 10.1161/CIRCULATIONAHA.106.681247.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe